ERBB2 and neuroblastoma: Until recently, a large majority of cell surface molecules that have been targeted with immune-based therapies across pediatric malignancies were either molecules that have been known for decades to be highly expressed on tumors, such as the disialoganglioside GD2 on neuroblastomas (Katano et al. 1983, Schulz et al. 1984) or CD19 on B cell leukemias, or molecules that have trickled down from adult oncology clinical trials, such as ERBB2 and CD20 (Sliwkowski & Mellman 2013).